# Supplementary Material

Supplementary Table. HIV Antiretroviral Therapies

| **Class** | **Drug name(s)** |
| --- | --- |
| CYP3A inhibitors | cobicistat |
| Entry inhibitors | maraviroc |
| Fusion inhibitors | enfuvirtide  |
| Integrase inhibitors | dolutegravirraltegravir elvitegravir |
| Multi-class combinations | efavirenz / emtricitabine / tenofovir DFemtricitabine / rilpivirine / tenofovir DFelvitegravir / cobicistat / emtracitabine / tenofovir DFabacavir / dolutegravir / lamivudine |
| NNRTIs | delavirdineefavirenznevirapinerilpivirineetravirine |
| NRTIs | emtricitabinelamivudinezidovudine, azidothymidinedidanosinetenofovir DFstavudineabacavirzalcitabine, dideoxycytidine  |
| NRTI combinations | lamivudine / zidovudineabacavir / lamivudineabacavir / lamivudine / zidovudineemtricitabine / tenofovir DF |
| Protease inhibitors  | amprenavirfosamprenavirtipranavirindinavirdarunavirsaquinavirsaquinavir mesylateritonaviratazanavirnelfinavir mesylate |
| Protease inhibitor combinations | lopinavir / ritonaviratazanavir / cobicistatdarunavir / cobicistat |

CYP3A, cytochrome P4503A; DF, disoproxil fumarate; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside/ nucleotide reverse transcriptase inhibitor.